Detalhe da pesquisa
1.
Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell
; 185(12): 2116-2131.e18, 2022 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35662412
2.
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Cell
; 185(3): 467-484.e15, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35081335
3.
The epitope arrangement on flavivirus particles contributes to Mab C10's extraordinary neutralization breadth across Zika and dengue viruses.
Cell
; 184(25): 6052-6066.e18, 2021 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34852239
4.
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
Cell
; 184(9): 2348-2361.e6, 2021 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730597
5.
Antibody evasion by the P.1 strain of SARS-CoV-2.
Cell
; 184(11): 2939-2954.e9, 2021 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33852911
6.
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
Cell
; 184(16): 4220-4236.e13, 2021 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34242578
7.
The antigenic anatomy of SARS-CoV-2 receptor binding domain.
Cell
; 184(8): 2183-2200.e22, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33756110
8.
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
Cell
; 184(8): 2201-2211.e7, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33743891
9.
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.
Cell
; 184(23): 5699-5714.e11, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34735795
10.
Author Correction: Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.
Nat Immunol
; 21(3): 354, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32001822
11.
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19.
Nat Immunol
; 21(11): 1336-1345, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32887977
12.
A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection.
Nat Immunol
; 20(10): 1291-1298, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31477918
13.
Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus.
Nat Immunol
; 19(11): 1248-1256, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30323338
14.
Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.
Nat Immunol
; 18(11): 1261-1269, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28945244
15.
Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+ T cell response.
Nat Immunol
; 18(11): 1228-1237, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28945243
16.
Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus.
Nat Immunol
; 17(9): 1102-8, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27339099
17.
A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.
Nat Immunol
; 16(2): 170-177, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25501631
18.
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Lancet
; 399(10324): 521-529, 2022 02 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35074136
19.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
; 398(10304): 981-990, 2021 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480858
20.
Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus.
Nat Immunol
; 16(7): 785, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26086146